通过UV触发的聚合在PLGA颗粒上的粘合性聚电解质涂层,以增强药物输送到炎症性肠粘膜
Jie Zhang1, Yi-Jing Yin2, Xing-Wang Wang2
1Department of Gastroenterology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Journal of nanobiotechnology
|January 23, 2025
概括
这项研究引入了一种用于性结肠炎 (UC) 的新型口服药物输送系统,使用带有特种涂层的塔克罗利斯载荷颗粒. 这种涂层增强了药物对炎症肠部位的粘附性,提高了治疗效率并减少了副作用.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 需要精确地将药物输送到炎症的肠部位,以最大限度地减少全身副作用.
- 在UC中炎症的肠粘膜具有带正电荷的氨基群,为专门的药物输送系统提供了目标.
- 目前对UC的治疗常常面临局部药物沉积和非目标效应的挑战.
研究的目的:
- 开发和评估一种口服药物输送系统,用于针对性地将塔克罗利斯 (TAC) 输送到性结肠炎 (UC) 中的炎症肠组织.
- 通过一种新的涂层策略,增强药物载荷颗粒对炎症结肠粘膜的附着性.
- 在急性结肠炎的临床前模型中提高塔克罗利斯的治疗疗效,同时最大限度地减少全身暴露.
主要方法:
- 制造含有塔克罗利斯 (TAC) 的聚 (乳糖合甘油酸) (PLGA) 纳米颗粒.
- 将TAC/PLGA纳米颗粒涂上聚烯酸和N-氧苏胺 (PAA-NHS) 通过在位UV触发的聚合.
- 在体外和体内评估颗粒对炎症肠道粘膜的粘附.
- 药物保留和治疗疗效的评估在硫酸 (DSS) 诱导的急性结肠炎小鼠模型中.
主要成果:
- 与未涂层颗粒相比,PAA-NHS涂层显著增强了PLGA颗粒对正电荷炎症肠道粘膜的附着性.
- 在大肠炎小鼠模型中,具有PAA-NHS涂层的TAC/PLGA颗粒表明,在炎症肠道内,塔克罗利斯的保留率更高.
- 针对性交付方法导致急性结肠炎的治疗效果得到改善,治疗结果得到改善.
结论:
- 开发的PAA-NHS涂层的TAC/PLGA纳米颗粒代表了针对性药物输送在性结肠炎管理中的有希望的战略.
- 这种方法有效地利用炎症粘膜的独特生化特性,改善药物局部化和治疗结果.
- 增强的粘附和保留可以最大限度地减少全身药物暴露,从而有可能减少UC治疗中的副作用.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
333
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
333
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
376
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
376


